INDICATION CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

This site is intended for US healthcare professionals only.
Crenessity logo, click to visit homepage
REAL EXPERIENCES OF EXPERTS AND PATIENTS

Hear directly from endocrinologists and patients about their CRENESSITY experience

Meet 3 CAH specialists

These providers talk about the challenges of treating CAH and their recent experiences prescribing CRENESSITY.

Click to learn more from Dr. Heidi SheaClick to learn more from Dr. Amrit BhangooClick to learn more from Dr. Run Yu

Select an endocrinologist’s image to learn more.

A lot of patients do come in, and they say, ‘Hey, what about this drug?’  This is an exciting opportunity to be able to give them something different, which we didn’t have before.”

A lot of patients do come in, and they say, ‘Hey, what about this drug?’  This is an exciting opportunity to be able to give them something different, which we didn’t have before.”

Dr. Heidi SheaAdult & Pediatric Endocrinologist

CANDID CAHNVERSATIONS

Impact of CRENESSITY

These experts discuss the challenges of managing CAH with GCs alone and share how CRENESSITY helps optimize treatment, potentially leading to better patient outcomes.

Impact of CRENESSITY

Candid CAHnversations

Impact of CRENESSITY

GC Down-Titration

Candid CAHnversations

GC Down-Titration

Who May Benefit From CRENESSITY

Candid CAHnversations

Who May Benefit From CRENESSITY

Initiating CRENESSITY

Candid CAHnversations

Initiating CRENESSITY

These physicians have been compensated by Neurocrine for sharing their views.

CLINICAL PROFILES FROM THE CAHTALYST® TRIALS

Kristy & Grant

Kristy shares her son Grant’s experience with CRENESSITY during the clinical trial—and beyond—including how much his androgen levels and GC dose dropped.

Kristy & Grant

Clinical Profiles

Kristy & Grant

Susan

Clinical Profiles

Susan

Paul

Clinical Profiles

Paul

Liam

Clinical Profiles

Liam

Ambassadors were compensated by Neurocrine for sharing their views.

PATIENT SATISFACTION WITH CRENESSITY1:

In a survey of 48 adults and 29 caregivers, when asked at the end of the open-label extension period1:

96% of adults and 94% of caregivers of children prefer a treatment plan with CRENESSITY over one without CRENESSITY.1*

96% of adults and 100% of caregivers of children were satisfied with taking CRENESSITY.1†

  • *Percentages include adult participants and caregivers of pediatric participants from the CAHtalyst® trials who "agreed" or "strongly agreed" that they prefer treatment with CRENESSITY over a treatment plan without CRENESSITY in the final treatment satisfaction survey.
  • †Percentage includes adult participants and caregivers of pediatric participants from the CAHtalyst® trials who rated their level of satisfaction with CRENESSITY as either "moderately satisfied" or "greatly satisfied" in the final treatment satisfaction survey.

Having the ability to be on less steroids provides peace of mind.” — Participant from Adult CAHtalyst® trial at the end of the open-label extension period

Having the ability to be on less steroids provides peace of mind.” — Participant from Adult CAHtalyst® trial at the end of the open-label extension period

SCIENCE OF CRENESSITY

Mechanism of Action

Watch the video to learn more about how CRENESSITY works in the CRF pathway.

Dosing

Review the dosing and administration information for CRENESSITY.

Support & Resources

Review dedicated support for you and your patients.

CAH=congenital adrenal hyperplasia; CRF=corticotropin-releasing factor; GC=glucocorticoid.

REFERENCE

INDICATION

CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

CONTRAINDICATIONS

CRENESSITY is contraindicated in patients with hypersensitivity to crinecerfont or any excipients of CRENESSITY.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions. A hypersensitivity reaction, including throat tightness, angioedema, and generalized rash, occurred in a subject after 3 days of treatment with CRENESSITY. If a clinically significant hypersensitivity reaction occurs, initiate appropriate therapy and discontinue CRENESSITY.

Risk of Acute Adrenal Insufficiency or Adrenal Crisis with Inadequate Concomitant Glucocorticoid Therapy. Acute adrenal insufficiency or adrenal crisis, which is potentially life-threatening, can occur in patients with underlying adrenal insufficiency who are on inadequate daily glucocorticoid doses, especially in situations associated with increased cortisol need, such as acute intercurrent illness, serious trauma, or surgical procedures. Continue glucocorticoids upon initiation of and during treatment with CRENESSITY. Do not reduce the glucocorticoid dose below the dose required for cortisol replacement. Patients should continue to use stress dosing of glucocorticoids in cases of increased cortisol need.

ADVERSE REACTIONS

In adult patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia.

In pediatric patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are headache, abdominal pain, fatigue, nasal congestion, and epistaxis.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths:

CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information.